UPCC 04726: Expanding Access to Advanced Immunophenotyping Using PhenoTa Analyzer

Enrolling By Invitation
99 years or below
All
Phase N/A
200 participants needed
1 Location

Brief description of study

PhenoTA proposes an automated solution for T, B, and NK cells, as well as other cell enumeration, identification and conditions, leveraging Raman spectroscopy, instead of traditional immunophenotypic and morphologic evaluation. This innovation aligns with the growing demand for rapid, cost-effective immunophenotyping and has the potential to transform standard hematology practice by bridging the gap between basic screening and advanced diagnostics.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 13 Jul 2026. Study ID: 25-2244
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator